Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.165 USD | +0.70% | +15.34% | +2.35% |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Apr. 02 | Goldman Sachs Adjusts Erasca's Price Target to $7 From $6, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.35% | 325M | |
+24.62% | 48.09B | |
+46.90% | 40.62B | |
-3.14% | 40.43B | |
-6.20% | 28.36B | |
+9.47% | 24.89B | |
-20.45% | 19.01B | |
+29.16% | 12.09B | |
+0.76% | 11.88B | |
-1.07% | 11.8B |
- Stock Market
- Equities
- ERAS Stock
- News Erasca, Inc.
- Erasca Doses First Patient in Trial Assessing Naporafenib Plus Trametinib in Patients With RAS Q61X Solid Tumors